Intellia Therapeutics (NTLA) used CRISPR gene editing to lower a troublesome protein in patients, but NTLA stock nosedived Tuesday on patent and competition questions.
XThe company’s CRISPR gene-edi… [+3960 chars]
NTLA Stock Crashes As Patent Decision Shadows CRISPR Gene-Editing Data – Investors Business Daily